Renal Solutions

About Renal Solutions

Renal Solutions, Inc. (RSI) was a medical device company established in 2000 that focused on developing treatments for patients with renal failure. The company's key innovation was sorbent-based hemodialysis technology, which it commercialized through its Allient® Sorbent Hemodialysis System. This system represented a significant advancement in the dialysis field by enabling effective hemodialysis using only six liters of ordinary drinking water, a substantial reduction from the 120 liters of purified water required by conventional machines. The technology works by regenerating and purifying the dialysate (dialysis fluid) with specialized sorbent compounds, which eliminates the need for complex and costly water purification systems.

The company's technology platform, named SMARRT™ (Sorbent Management for Advanced Renal Replacement Therapy), provided flexibility for short, standard, or extended duration therapies. In June 2005, RSI received FDA 510(k) clearance to commercialize the Allient® System for both chronic and acute hemodialysis applications. A key milestone was the acquisition of the company by Fresenius Medical Care AG & Co. KGaA on November 29, 2007. The deal was valued at up to $190 million, consisting of $100 million at closing, with subsequent milestone payments. At the time of the acquisition, Peter DeComo was the President and CEO of Renal Solutions.

The acquisition was a strategic move for Fresenius, the world's largest provider of dialysis products and services, to enhance its home hemodialysis offerings and invest in the development of a wearable artificial kidney. Following the acquisition, RSI continued its operations as a wholly owned subsidiary, with its leadership remaining in place to steer its facilities in Warrendale, PA, and Oklahoma City, OK. The integration aimed to combine RSI's sorbent technology with Fresenius's manufacturing and market leadership to accelerate the development of next-generation home and acute dialysis products.